Publication: High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4+ naive lymphocytes and prevents TTV reactivation
| Reference | |
|---|---|
| Title | High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4+ naive lymphocytes and prevents TTV reactivation |
| Topic | Zinc |
| Author | Iovino, L, Mazziotta, F, Carulli, G, Guerrini, F, Morganti, R, Mazzotti, V, Maggi, F, Macera, L, Orciuolo, E, Buda, G, Benedetti, E, Caracciolo, F, Galimberti, S, Pistello, M, Petrini, M |
| Year | 2018 |
| Journal | Leukemia Research |
| DOI | https://doi.org/10.1016/j.leukres.2018.04.016 |
Author's Abstract The abstract and the information and conclusions contained therein were written by the authors of the publication.
| Introduction: Zinc plays an important role in thymic function and immune homeostasis. We performed a pro- spective clinical trial using a high-dose zinc oral supplementation to improve the immune reconstitution after hematopoietic stem cell transplant (HSCT).
Patients and methods: We enrolled 18 patients undergoing autologous HSCT for multiple myeloma. Nine patients were randomized to receive only a standard antimicrobial prophylaxis; whereas, nine patients received in ad- dition 150 mg/day of zinc from day +5 to day +100 after transplant. Results: CD4+ naïve lymphocytes and TRECs showed a significant increase from day +30 until day +100 only in the zinc-treated group. Moreover, the load of Torquetenovirus, a harmless virus that replicates in course of immunedepression, increased at day +100 only in the control group. No severe adverse events were reported during the zinc consumption. Conclusion: First data from the ZENITH trial suggest that high-dose zinc supplementation is safe and may en- hance the thymic reconstitution after HSCT. |
This publication is referenced in the following studies: